Cytochrome P4503A4 (CYP3A4) is the most abundant cytochrome P450 in adult human liver and small intestine and oxidizes numerous clinically, physiologically, and toxicologically important compounds. The metabolic activity of CYP3A4 in patients varies at least 10-fold in vivo, and CYP3A4 genetic variants are considered one of the causes of individual differences. The cDNAs for the CYP3A4*2 (S222P), *7 (G56D), *16 (T185S), and *18 (L293P) mutant alleles, found in high frequencies in Caucasians or Asians, were constructed by site-directed mutagenesis and expressed in an Escherichia coli expression system. Midazolam (MDZ), testosterone (TST), and nifedipine (NIF) were used to assess the catalytic activities of the CYP3A4 wild type (CYP3A4.1) and its variants. The catalytic activities of CYP3A4.2 and CYP3A4.16 were reduced (lower V max and increased K m relative to CYP3A4.1) for all substrates. The CYP3A4.7 showed lower V max values for MDZ and NIF (60 and 84%, respectively) and a higher K m (2-fold) for TST but not for MDZ or NIF. Although CYP3A4.18 showed low V max values for MDZ, NIF, and TST (88, 72, and 80% of CYP3A4.1, respectively), no significant differences were identified in the ratio V max/Km . In summary, CYP3A4.2 and CYP3A4.16 exhibited significantly lower activity for MDZ, TST, and NIF oxidations than CYP3A4.1. Therefore, drugs metabolized by only CYP3A should be carefully administered to patients with these alleles.
The CYP3A subfamily of cytochrome P450 enzymes comprises approximately 30 to 60% of total cytochrome P450 in human liver (Shimada et al., 1994) . The CYP3A enzymes are responsible for the metabolism of more than 50% of clinically used drugs and also some steroids and environmental chemicals (Li et al., 1995; Evans and Relling, 1999; Guengerich, 1999) . Four human CYP3A enzymes-CYP3A4, CYP3A5, CYP3A7, and CYP3A43-have been identified, and CYP3A4 is regarded as the most dominant CYP3A enzyme in the liver and small intestine (Wrighton et al., 1990; Shimada et al., 1994; Hustert et al., 2001; Koch et al., 2002) . It has been reported that CYP3A4 expression shows large interindividual variation (Guengerich, 1999; Ozdemir et al., 2000; Lin et al., 2002) and that these variations can lead to different responses to human drugs that are substrates for CYP3A4. Because the expression of CYP3A4 and CYP3A5 can be induced by pregnane X receptor, constitutive androstane receptor, and glucuronide receptor ligands, both environmental and genetic factors can influence the CYP3A activity; however, the genetic contribution has been estimated to be larger (Ozdemir et al., 2000) , suggesting that polymorphisms in CYP3A4 may predict CYP3A phenotype, at least in part. Genetic analysis is needed to understand interindividual variability. Extensive studies searching allelic variants in the coding regions of CYP3A4 have been done, and currently 20 different CYP3A4 variant proteins have been described, some of them representing proteins of either decreased or increased activity. Those polymorphisms are reported on the Human Cytochrome P450 (P450) Allele Nomenclature Committee Web site (http://www.cypalleles. ki.se/cyp3a4.htm). Decreased activities for the CYP3A4*8, *11, *12, *13, *16 , and *17 alleles, increased activity of CYP3A4*18, and lack of expressed protein for CYP3A4*20 are indicated. However, there are some conflicting reports, depending on the substrates or experimental systems.
To identify the effect of genetic variation on catalytic activity of CYP3A4, we expressed CYP3A4*1 (wild type), *2 (2.7% in Caucasian) (Sata et al., 2000) , *7 (1.4 -3% in Caucasian) Lamba et al., 2002) , *16 (1.4 -5% in Japanese) Fukushima-Uesaka et al., 2004) , and *18 (1.3-2.8% in Japanese) (Dai et al., 2001; Yamamoto et al., 2003; Fukushima-Uesaka et al., 2004) in Escherichia coli using a bacterial cDNA expression system. This system highly expresses functional CYP3A4 protein cost effectively (Parikh et al., 1997) . Catalytic activities of wild-type CYP3A4 and allelic variants were compared using the clinically used drugs midazolam (MDZ) and nifedipine (NIF) and an endogenous CYP3A4 substrate, testosterone (TST), as typical CYP3A4 substrates. expressed CYP3A4 were purchased from BD Gentest (Woburn, MA). Primers were purchased from KURABO Industries Ltd. (Osaka, Japan). Nifedipine and hydrocortisone were purchased from Sigma-Aldrich (St. Louis, MO). Leupeptin, TST, and isopropyl-␤-D(Ϫ)-thiogalactopyranoside were purchased from Wako Pure Chemicals (Osaka, Japan). Mouse anti-human CYP3A4, rabbit anti-mouse IgG antibodies, 1Ј-hydroxymidazolam, 6␤-hydroxy-TST, and 2,6-dimethyl-4-(2Ј-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester (oxidized nifedipine) were purchased from Daiichi Pure Chemical (Tokyo, Japan). Midazolam injections (Dormicum injections) were purchased from Astellas Pharma Inc. (Tokyo, Japan) and used (in in vitro studies) without purification. Diazepam was purchased from Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan). All other chemicals and reagents were of analytical grade and were obtained from commercial sources and used without further purification.
Modification of CYP3A4 cDNA. The expression vectors pCW-OR and pBL3A4 were described previously (Parikh et al., 1997) and were digested by NdeI and XbaI. To achieve expression, the N terminus of protein was modified as described by Parikh et al. (1997) and Guengerich et al. (1996) . After electrophoresis on a 2% agarose gel, bands at 7025 base pairs (pCW-OR vector) and 1500 base pairs (CYP3A4 cDNA) were cut out. DNA fragments were extracted with a QIAEX II gel extraction kit (QIAGEN, Valencia, CA), and those fragments were ligated with a DNA ligation kit (TAKARA, Otsu, Japan) to construct wild-type pCW3A4bc, the plasmid for expressing CYP3A4 and NADPH-P450 reductase (OR) bicistronically.
Site-Directed Mutagenesis. Expression vectors for CYP3A4.2 (S222P), 0.7 (G56D), 0.16 (T185S), and 0.18 (L293P) were made using site-directed mutagenesis. A QuikChange site-directed mutagenesis kit from Stratagene (La Jolla, CA) was used to introduce single nucleotide changes (primers used to introduce single nucleotide polymorphisms are available upon request). The entire coding region, including the mutated sites, was confirmed by direct sequencing. The entire cDNA was then excised and subcloned into a new pCW/OR plasmid to avoid any accidental mutations in the plasmid caused by the mutagenesis procedure.
Expression of CYP3A4s and Preparation of Membrane Fraction of E. coli. Expression of CYP3A4 wild-type and variant proteins in E. coli DH5␣ FЈIQ cells and preparation of the membrane fraction were carried out according to Gillam et al. (1993) . After determination of the protein content according to Lowry et al. (1951) with a DC protein assay kit (Bio-Rad, Hercules, CA), the P450 content was determined by the CO difference spectra method of Omura and Sato (1964) as modified by Iwata et al. (1998) , after dilution of the suspension with 100 mM of potassium phosphate buffer (pH 7.4) containing 20% (v/v) glycerol and 0.2% (w/v) Emulgen 911. The difference spectra were recorded by using a Shimadzu UV-visible spectrophotometer model MPS-1600. The membrane fractions were frozen and stored at Ϫ80°C until use. Three lots of membrane fractions expressing wild-type or the variants of CYP3A4 were used in further experiments.
Immunoblot Analysis. SDS-polyacrylamide gel electrophoresis and Western blotting were performed according to the methods of Guengerich et al. (1982) with 12% (w/v) polyacrylamide gels. Immunodetection was performed with a WB-MAB3A/human CYP3A4/3A5 WB kit according to the manufacturer's instructions, using diaminobenzidine as the peroxidase substrate.
Enzyme Activity. MDZ 1Ј-hydroxylation activity was determined as described by Yamaori et al. (2004) . The reaction mixture (total 450 l) for the assay consisted of 0.1 M potassium phosphate buffer (pH 7.4), 0.1 mM EDTA, an NADPH-generating system (5.0 mM glucose 6-phosphate, 0.5 mM NADP ϩ , and 1 unit/ml glucose 6-phosphate dehydrogenase) and membrane fraction (0.025 nmol of P450). After preincubation at 37°C for 5 min, the reaction was initiated by addition of 50 l of midazolam in 50% methanol (0 -150 M final concentration). The reaction mixture was incubated at 37°C for 5 min, and the reaction was terminated by adding 500 l of ice-cold acetonitrile, followed by the addition of 50 l of 10 mg/ml diazepam as an internal standard. After centrifugation at 3500 rpm for 20 min, the concentration of 1Ј-hydroxy-MDZ in the supernatant was determined by HPLC.
NIF oxidation and TST 6␤-hydroxylation activities were determined as for MDZ 1Ј-hydroxylation with minor modifications. After preincubation, the reaction was initiated by the addition of 50 l of NIF or TST in 50% methanol (0 -250 and 0 -500 M final concentrations, respectively), and the reaction mixtures were incubated at 37°C for 10 min. Ice-cold acetonitrile was added to terminate the reaction, followed by the addition of 50 l of 100 mg/ml diazepam and 2 mM hydrocortisone, respectively, as internal standards. After centrifugation, the concentration of oxidized NIF or 6␤-hydroxy-TST in the supernatants was determined by HPLC.
Measurement of Metabolites by HPLC. Concentrations of 1Ј-hydroxy-MDZ were determined according to the method of Qi et al. (2005) . Oxidized NIF and 6␤-hydroxy-TST were determined using similar conditions. For the determination of oxidized NIF and 6␤-hydroxy-TST, an Intersil ODS-2 (4.6 ϫ 150 mm) column was used with a gradient system beginning with methanolwater (45:55, v/v) . From 0 to 10 min, the acetonitrile concentration was programmed to linearly increase from 0 to 25% (v/v) during 10 min and then returned to the starting mobile phase from 10 to 12 min. The absorbance of oxidized NIF and 6␤-hydroxy-TST were detected at 220 and 239 nm, respectively.
Data Analysis. The kinetic parameters K m and V max were estimated by analyzing Michaelis-Menten plots using GraphPad Prism software (version 4.0; GraphPad Software Inc., San Diego, CA). The equation v ϭ V max S/(K m ϩ S) was fitted to the measured data for initial velocity (v) at varying concentrations of substrate (S) using nonlinear regression. Values of steadystate catalytic parameters are considered as the ratio V max /K m . Statistical comparisons were made with Student's t test with the Bonferroni revision, and differences were considered statistically significant when the p value was Ͻ0.05. FIG. 1 . A, immunoblot analysis of expressed CYP3A4s. M, molecular weight standard, BenchMark Pre-stained protein ladder (Invitrogen); lanes 1 and 2, human liver microsome (50 and 10 g of microsomal protein, respectively); lanes 3 and 4, human CYP3A4 and OR microsomes (10 and 5 g of microsomal protein) expressed in human B lymphoblastoid cell line; lane 5, wild-type CYP3A4 expressed in E. coli membrane fraction; lane 6, CYP3A4.2 expressed in E. coli membrane fraction; lane 7, CYP3A4.7 expressed in E. coli membrane fraction; lane 8, CYP3A4.16 expressed in E. coli membrane fraction; lane 9, CYP3A4.18 expressed in E. coli membrane fraction; lane 10, membrane fraction of E. coli transformed by pCW-OR vector as a negative control; Wild-type and variants were loaded (10 g of membrane protein) on 12% polyacrylamide gel. After electrophoresis, the proteins were transferred to a polyvinylidene fluoride membrane and probed with anti-human CYP3A4/3A5 Ig as described under Materials and Methods. B, relative band intensity of immunoblot analysis expressed CYP3A4s. C, carbon monoxide difference spectra of E. coli membrane fractions expressing CYP3A4 wild type and variants. Each sample contained 1.6 nmol of P450/ml.
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Results

Expression of Wild-Type and Variant CYP3A4s in E. coli. The introduction of four SNPs into CYP3A4 cDNAs was confirmed by direct sequencing (data not shown). The expression levels of CYP3A4
proteins in membrane fractions obtained from E. coli DH5␣ FЈIQ transformed with CYP3A4*1 (wild-type), CYP3A4*2, CYP3A4*7, CYP3A4*16, and CYP3A4*18 were examined by reduced CO difference spectral and immunoblot analyses. As shown in Fig. 1C , the reduced CO difference spectra of CYP3A4s showed Soret peaks at 450 and approximately 420 nm. The expression levels of wild-type and variant CYP3A4 proteins in E. coli membrane fractions were also assessed by immunoblotting. The stained CYP3A4 bands were at 52 kDa, the same as human liver microsomes or CYP3A4 expressed by a baculovirus-insect cell system containing CYP3A4 cDNA. (Fig.  1A) . The expression levels of CYP3A4*1 and variants did not differ in three independent expressions.
Comparison of Activities of Wild-Type and Variant CYP3A4s Expressed in E. coli. The MDZ 1Ј-hydroxylation, NIF oxidation, and TST 6␤-hydroxylation activities of CYP3A4.1, CYP3A4.2, CYP3A4.7, CYP3A4.16, and CYP3A4.18 were examined. The relationships between substrate concentrations and reaction velocities are shown in Fig. 2 , and the V max and K m values are compiled in Table 1 . The V max /K m values, which predict intrinsic clearance in vivo, were calculated and compared with those for CYP3A4.1. The activities of CYP3A4.2 and CYP3A4.16 were reduced (lower V max and increased K m relative to CYP3A4.1) for all substrates. CYP3A4.7 had a decreased V max for MDZ and NIF (to 60 and 84%, respectively) and increased (2-fold) K m for TST but not for MDZ or NIF. Although CYP3A4.18 showed a reduced V max for MDZ, NIF, and TST (to 88, 72, and 80%, respectively), no significant differences were identified in the ratio V max /K m .
Discussion
A wide interindividual variability exists in CYP3A substrate clearance in vivo (Wrighton et al., 1990; Shimada et al., 1994; Kuehl et al., 2001; Koch et al., 2002) , but there is very limited evidence linking individual genetic polymorphisms to variations in metabolism. The present study shows that recombinant CYP3A4.2 (S222P) is decreased (to 37%, V max ) for NIF oxidation, with a 3.4-fold increased K m , compared with wild type, and this result indicated lower activity for NIF than for the other two substrates. In a previous study, recombinant CYP3A4.2 exhibited a lower V max for NIF metabolism (ϳ36% decrease) but not for TST compared with CYP3A4 wild type (Sata et al., 2000) . In the present study, expressed CYP3A4.2 is markedly defective in the oxidation of TST (Table 1) . The difference with the previous work (Sata et al., 2000) may be the result of the difference in the range of substrate concentrations, expression level of reductase, and other factors in the reaction mixture. The mechanism of the change in kinetics on metabolism of the CYP3A4 substrates may be caused by the disruption of protein conformation by the serine to proline substitution. Codon 222 in CYP3A4.2 is located in the loop between helices F and G, and proline could bend the loop structure to result in influences on substrate access to the substrate recognition site or interaction with the E. coli membrane. The loop between helices F and G in eukaryotic P450s, including CYP3A4, is thought to form a membrane interaction domain (Williams et al., 2000) . In a previous study, a CYP3A4*2 homozygous individual was found in the group of slow metabolizers for cortisol 6␤-hydroxylation (Shchepotina et al., 2006) . It is predicted that the CYP3A4*2 allele may result in lower CYP3A4 activity in vivo, although in vivo activity of this allele for NIF oxidation has not been reported.
The present study shows that recombinant CYP3A4.16 is markedly defective in MDZ, NIF, and TST oxidation in vitro, exhibiting approximately 65% decreases in V max and increased K m values (3.6-to 5.9-fold) compared with the wild type. This result is consistent with a report that the CYP3A4*16 allele caused a 60% decrease activity in TST 6␤-hydroxylation (Murayama et al., 2002) . In the comparison between CYP3A4.1 and CYP3A4.16, CYP3A4.16 showed lower activity than in the report from Murayama et al. (2002) . Possible reasons for this disagreement are differences in the experimental systems, i.e., FIG. 2. Kinetics of CYP3A4 activity in E. coli membrane fractions expressing wild type or variants. A, MDZ 1Ј-hydroxylation. B, NIF oxidation. C, TST 6␤-hydroxylation. The Michaelis-Menten equation was fit to the data points as described under Materials and Methods. Kinetic parameters for wild-type CYP3A4 and variants are shown in Table 1 . Oxidation activities represent the mean Ϯ S.D. from nine independent experiments. The substrate concentrations were 0 to 150, 0 to 250, and 0 to 500 M, respectively. F, wild-type CYP3A4; f, CYP3A4.2; OE, CYP3A4.7; , CYP3A4.16; }, CYP3A4.18.
TABLE 1
Kinetic parameters of midazolam, nifedipine, and testosterone oxidation in CYP3A4 wild type and variants
Values are mean Ϯ S.E. of kinetic parameters.
Midazolam 1Ј-Hydroxylation
Nifedipine Oxidation Testosterone 6-Hydroxylation (Lee et al., 2005) . The amino acid changes in CYP3A4.16 (T185S) and CYP3A4.17 (F189S) are located in helix E and appear to be involved in packing with residues on helices G and H and the turn between helices G and H (Yano et al., 2004) . The region including these amino acids can be significant for CYP3A4 catalytic activities, even though these amino acids are not located in the putative substrate recognition site of CYP3A4 reported previously (Gotoh, 1992; Wang et al., 1998; Khan et al., 2002) . The residues of CYP3A4.16 and CYP3A4.17 are nonconservative mutations in tightly packed regions, which could conceivably affect the conformation of the protein, substrate access, and/or catalytic activity. In both the present and a previous study, recombinant CYP3A4.16 and CYP3A4.17 showed large peaks around 420 nm in the CO difference spectra compared with wild-type or other variant CYP3A4s. These mutations could result in influences on other parts of the protein and conformational changes that affect stability and indirectly affect activity.
The CYP3A4*16 allele has been reported at a frequency of 1.4 to 5% in Asians and other ethnic groups Fukushima-Uesaka et al., 2004) , so marked in vitro changes in metabolic activity provide important information for pharmacotherapeutics. However, there have been no reports suggesting that the CYP3A4*16 allele causes changes in activity in vivo because the CYP3A4*16 allele has been detected only in heterozygotes. Thus, the clinical relevance of the CYP3A4*16 homozygote remains to be further evaluated. CYP3A4*16 in the homozygote state (in vivo) would be expected to reduce the enzyme activity and produce a "slow metabolizer" or "poor metabolizer" phenotype, such as CYP3A4*2. Furthermore, the contribution of other drug-metabolizing enzymes can lead to underestimation of genetic influence. The CYP3A4 substrates demonstrating small renal excretion or high specificity for CYP3A4 should be administrated with some caution.
The present study shows that recombinant CYP3A4*7 is defective in testosterone metabolism in vitro, exhibiting an increase in K m compared with the wild type. However, no differences were identified in the V max /K m ratio between the substrates.
Although the CYP3A4*7 allele was found at a 1.4 to 3% allele frequency in Caucasians, no other report has been published about activities in vivo or in vitro. Our present study suggests that the CYP3A4*7 allele does not cause differences in catalytic activity in the three typical CYP3A4 substrates, and additional work is needed to further define the property of this allele.
Recombinant CYP3A4.18 exhibited a 2-fold higher activity toward TST and the insecticide chlorpyrifos in an earlier study (Dai et al., 2001) . However, this variant showed no significant change in metabolism of MDZ, TST, or NIF compared with the wild type in the present study, in support of reports from Murayama et al. (2002) and Lee et al. (2005) . Although the CYP3A4*18 allele has been found with 1.3 to 2.8% allele frequency in Asians (Dai et al., 2001; Yamamoto et al., 2003; Fukushima-Uesaka et al., 2004) , the possibility that CYP3A4*18 allele causes individual differences of CYP3A4 activity is considered to be low.
In the present study, genetic effects of CYP3A4 polymorphisms on catalytic activities were investigated with membrane fractions from E. coli expression systems and, therefore, the effects of regulation of mammalian expression or protein stability could not be detected. Also, when the enzymatic activities are markedly decreased in vitro, the genetic effects of CYP3A4 polymorphisms may not be detected when other relevant metabolic pathways are present in vivo. In summary, the CYP3A4*2 and CYP3A4*16 alleles exhibited a significantly lower catalytic activity for the diagnostic substrates MDZ, NIF, and TST than CYP3A4*1 (wild type). These alleles may potentially contribute to the known variability in the metabolism of clinically used drugs and environmental compounds that are CYP3A4 substrates, and thus drugs oxidized by CYP3A should be carefully administered to patients with these alleles.
